Licensing & partnerships
Aclara is actively interested in licensing its photoreactive nanofiber filtration platform, in manufacturing partnerships, and in conversations with strategic acquirers. Whatever the structure, what transfers is the same: the patents, the exclusive worldwide university license, the process know-how from the 2022 production run, the commercial record, and an FDA program in preparation.
The record
Invented at GWU & UC Riverside; peer-reviewed in Environmental Science & Technology (ACS, 2022).
U.S. Patent 11,975,221 issued; allowed in Canada; pending EU/UK; exclusive worldwide license. Details →
≈117,000 masks produced in an industrial run; U.S. media and finished-goods path in qualification. Details →
Finished products sold through a national distributor channel at proven margins. Details →
Two FDA Q-Submissions completed; 510(k) premarket notification in preparation on a Class II pathway with predicates. Details →
Options
License the patent estate and process know-how for your field and territory, for filtration manufacturers, healthcare companies, and strategics who can carry the media into their own product lines.
Partner on the U.S. production ramp, co-develop new form factors or chemistries on the platform, or supply the media into your applications.
The company is open to conversations with strategic acquirers. The patents, the exclusive license, the manufacturing know-how, the commercial record, and the FDA program all sit inside one Delaware C-corporation ready to transfer.
Start the conversation
Licensing, partnership, and acquisition inquiries are handled directly by the company’s leadership. Email us and you will reach a decision-maker, not a form.
A detailed data room is available to qualified parties under NDA.